Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

Photobiomodulation therapy increases neural stem cell pool in aged 3xTg-AD mice

Our results show that one month of PBM therapy reduces hyperphosphorylated tau burden and partially rescues AHN in aged 3xTg-AD mice as compared to SHAM-treated transgenic mice.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors studied aged 3xTg-AD mice, a model of advanced Alzheimer's neuropathology, randomized to one month of 670 nm photobiomodulation or sham therapy. They report that photobiomodulation reduced hyperphosphorylated tau burden and partially rescued adult hippocampal neurogenesis compared with sham-treated mice. The findings come from an animal study, so their relevance to human patients is not established.

Who or what was studied
Aged 3xTg-AD transgenic mice, 15 to 17 months old
Wavelengths
670 nm
Limits stated in the abstract
The study was conducted in mice, and the abstract does not report a total sample size.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Presently approved Alzheimer's Disease (AD) therapeutics are designed for targeted removal of the AD-related toxic protein aggregate amyloid-β (Aβ) and have only shown moderate efficacy at slowing disease progression. Reversal of cognitive decline requires both removal of toxic aggregates and repair of the cellular systems damaged by decades of exposure to these aggregates. Adult hippocampal neurogenesis (AHN) is one such system that is known to be affected early and severely in the development of AD. Moreover, preserved AHN is associated with cognitive resilience to AD neuropathology. Therefore, targeted therapies to improve or enhance neurogenesis should be considered in addition to the removal of toxic protein aggregates. Photobiomodulation (PBM) using 670 nm LED light has been shown to induce synaptic resilience to and removal of AD-related toxic protein aggregates. In this study, we aimed to assess the effect of PBM on a mouse model of advanced AD neuropathology. Transgenic 3xTg-AD mice (15- to 17-month old) were randomized to receive PBM or SHAM therapy for one month, followed by neuropathological assessments. Our results show that one month of PBM therapy reduces hyperphosphorylated tau burden and partially rescues AHN in aged 3xTg-AD mice as compared to SHAM-treated transgenic mice. These data support the notion that PBM has the potential to be an effective non-invasive therapy to help preserve AHN and reduce cognitive dysfunction in moderate to advanced AD.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Wavelength
670 nm

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Sham, Light-emitting diode, Cognitive decline. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies